» Articles » PMID: 35183220

Diagnostic Yield of Next-generation Sequencing in 87 Families with Neurodevelopmental Disorders

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2022 Feb 20
PMID 35183220
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neurodevelopmental disorders (NDDs) are a group of heterogeneous conditions, which include mainly intellectual disability, developmental delay (DD) and autism spectrum disorder (ASD), among others. These diseases are highly heterogeneous and both genetic and environmental factors play an important role in many of them. The introduction of next generation sequencing (NGS) has lead to the detection of genetic variants in several genetic diseases. The main aim of this report is to discuss the impact and advantages of the implementation of NGS in the diagnosis of NDDs. Herein, we report diagnostic yields of applying whole exome sequencing in 87 families affected by NDDs and additional data of whole genome sequencing (WGS) from 12 of these families.

Results: The use of NGS technologies allowed identifying the causative gene alteration in approximately 36% (31/87) of the families. Among them, de novo mutation represented the most common cause of genetic alteration found in 48% (15/31) of the patients with diagnostic mutations. The majority of variants were located in known neurodevelopmental disorders genes. Nevertheless, some of the diagnoses were made after the use of GeneMatcher tools which allow the identification of additional patients carrying mutations in THOC2, SETD1B and CHD9 genes. Finally the use of WGS only allowed the identification of disease causing variants in 8% (1/12) of the patients in which previous WES failed to identify a genetic aetiology.

Conclusion: NGS is more powerful in identifying causative pathogenic variant than conventional algorithms based on chromosomal microarray as first-tier test. Our results reinforce the implementation of NGS as a first-test in genetic diagnosis of NDDs.

Citing Articles

Expanding the mutational spectrum of ReNU syndrome: insights into 5' Stem-loop variants.

Bruselles A, Mancini C, Chiriatti L, Carvetta M, Baroni M, Cappelletti C Eur J Hum Genet. 2025; .

PMID: 40011755 DOI: 10.1038/s41431-025-01820-1.


Whole Exome Sequencing and Panel-Based Analysis in 176 Spanish Children with Neurodevelopmental Disorders: Focus on Autism Spectrum Disorder and/or Intellectual Disability/Global Developmental Delay.

Sanchez Suarez A, Martinez Menendez B, Escolar Escamilla E, Martinez Sarries F, Esparza Garrido M, Gil-Fournier B Genes (Basel). 2024; 15(10).

PMID: 39457434 PMC: 11508026. DOI: 10.3390/genes15101310.


Identification of diagnostic candidates in Mendelian disorders using an RNA sequencing-centric approach.

Oquendo C, Wai H, Rich W, Bunyan D, Thomas N, Hunt D Genome Med. 2024; 16(1):110.

PMID: 39252027 PMC: 11382415. DOI: 10.1186/s13073-024-01381-w.


SpliceVarDB: A comprehensive database of experimentally validated human splicing variants.

Sullivan P, Quinn J, Wu W, Pinese M, Cowley M Am J Hum Genet. 2024; 111(10):2164-2175.

PMID: 39226898 PMC: 11480807. DOI: 10.1016/j.ajhg.2024.08.002.


Optical genome mapping identifies a homozygous deletion in the non-coding region of the SCN9A gene in individuals from the same family with congenital insensitivity to pain.

Boughalem A, Ciorna-Monferrato V, Sloboda N, Guegan A, Page F, Zimmer S Front Genet. 2024; 15:1375770.

PMID: 39156962 PMC: 11327051. DOI: 10.3389/fgene.2024.1375770.


References
1.
Srivastava S, Love-Nichols J, Dies K, Ledbetter D, Martin C, Chung W . Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019; 21(11):2413-2421. PMC: 6831729. DOI: 10.1038/s41436-019-0554-6. View

2.
Lim E, Uddin M, De Rubeis S, Chan Y, Kamumbu A, Zhang X . Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. Nat Neurosci. 2017; 20(9):1217-1224. PMC: 5672813. DOI: 10.1038/nn.4598. View

3.
Rodenburg R . The functional genomics laboratory: functional validation of genetic variants. J Inherit Metab Dis. 2018; 41(3):297-307. PMC: 5959958. DOI: 10.1007/s10545-018-0146-7. View

4.
Deng Y, Pan W . Significance Testing for Allelic Heterogeneity. Genetics. 2018; 210(1):25-32. PMC: 6116971. DOI: 10.1534/genetics.118.301111. View

5.
Kumar R, Gardner A, Homan C, Douglas E, Mefford H, Wieczorek D . Severe neurocognitive and growth disorders due to variation in THOC2, an essential component of nuclear mRNA export machinery. Hum Mutat. 2018; 39(8):1126-1138. PMC: 6481655. DOI: 10.1002/humu.23557. View